HOME >> BIOLOGY >> NEWS
Interim data suggest major response with Aranesp(R) in anemic patients with MDS

THOUSAND OAKS, Calif., Jul 06, 2005 (BUSINESS WIRE) -- Amgen Inc. (NASDAQ:AMGN), the world's largest biotechnology company, today announced new interim data from a Phase 2 study evaluating the use of 500 mcg of Aranesp(R) (darbepoetin alfa) every three weeks to treat anemia in patients with a bone marrow disorder known as myelodysplastic syndromes (MDS). The data were presented at the 17th International Symposium of the Multinational Association of Supportive Care in Cancer (MASCC) in Geneva. (Abstract #02-007)

"The majority of MDS patients develop clinically significant anemia during the course of their disease, which often leads to fatigue and increased red blood cell transfusions," said Janice Gabrilove, M.D., professor of medicine, hematology and medical oncology at Mount Sinai School of Medicine, New York and the study's lead investigator. "In this study, low risk MDS patients receiving Aranesp every three weeks, who had no prior erythropoietic therapy, exhibited an overall response of 77 percent, increased hemoglobin levels and improvements in patient reported fatigue."

Results of an interim analysis were presented from the first 100 patients of an approximately 200 patient, Phase 2, single arm study of low risk MDS patients (those with a low risk of progressing to acute myeloid leukemia) with anemia and treated with Aranesp 500 mcg administered every three weeks. Of the 100 patients evaluated, 63 percent had no prior erythropoietic agent use. The primary endpoint of the study was the proportion of patients achieving an erythroid response (defined in accordance with the International Working Group Response Criteria) during the 13-week test period. Secondary endpoints included changes in hemoglobin level from baseline, incidence of transfusions and impact on patient reported fatigue.

Results were presented for all 100 patients for incidence of transfusion and patient reported fatigue and 90 patients were evaluated for erythroid respon
'"/>

Contact: Trish Hawkins
plange@amgen.com
805-447-5631
Porter Novelli
6-Jul-2005


Page: 1 2 3 4

Related biology news :

1. Interim analysis of anti-cancer vaccine, BiovaxID, to be conducted
2. Interim Aranesp data suggest major response in anemic patients with MDS
3. Interim long-term follow-up data show AMG 531 increases platelets in patients with ITP
4. Features of replication suggest viruses have common themes, vulnerabilities
5. New study suggests Concord grape juice may provide protection against breast cancer
6. Study suggests estrogen deficiency can lead to obesity-induced high blood pressure after menopause
7. Experiment suggests limitations to carbon dioxide tree banking
8. Immunity in social amoeba suggests ancient beginnings
9. New model for autism suggests women carry the disorder and explains age as a risk factor
10. Pediatric ritalin use may affect developing brain, new study suggests
11. Oldest DNA ever recovered suggests earth was warmer than previously believed

Post Your Comments:
(Date:11/4/2014)... published research study examining only marketing directed at ... food restaurants has found that the majority of ... to such marketing tactics. , Authored by Arizona ... the study is the first to examine the ... exterior of fast food restaurants and its relationship ...
(Date:11/3/2014)... , Nov. 3, 2014 Research and Markets ... "Cell Therapy - Technologies, Markets and Companies" to their ... therapy technologies and methods, which have already started to play ... cell transplantation is replacing the old fashioned bone marrow transplants. ... therapy is bound to become a part of medical practice. ...
(Date:11/2/2014)... issue of Physics World , James Dacey explores ... of death" to take their innovations from the lab ... gruelling challenge facing all start-up companies as they move ... because of two main factors: physics-based inventions are usually ... turn out to be a lot more complicated than ...
Breaking Biology News(10 mins):Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3The 'valley of death' facing physics start-ups 2
(Date:11/21/2014)... 20, 2014 The report, ... Oligos, Enzymes, Cloning kits), Technology (Bioinformatics, Nanotechnology, ... Pharmaceuticals, Biomaterials, Bioremediation) - Global Forecast to ... drivers, threats, opportunities, and challenges. , Browse ... spread through 185 pages and in-depth TOC ...
(Date:11/21/2014)... 2014 2014 Deep Research Report ... in-depth research report on the transformer market. The ... application, and industry chain structure as well as ... analysis, including China’s domestic market as well as ... situation analysis. The report also covers information on ...
(Date:11/18/2014)... Calif. , Nov. 18, 2014 Cord ... platinum sponsor of the 10th Annual World Stem Cell Summit, ... medicine stakeholders. The 2014 World Stem Cell Summit will be ... San Antonio, Texas . The ... and development of lifesaving cures and therapies, convening the most ...
(Date:11/18/2014)... NJ (PRWEB) November 18, 2014 ... Quality and Transparency Reporting solutions, announced today that ... live using its Consummate Provider™ solution in both ... is a Global, SaaS based, Data Quality remediation ... and their third party Providers improve their ability ...
Breaking Biology Technology:Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 2International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 3Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2
Cached News: